Details are available for 43 cases of COVID-19 attributed to the Omicron variant;
25 (58%) were in persons aged 18–39 years.
The earliest date of symptom onset was November 15 in a person with a history of international travel.
Fourteen (33%) persons reported international travel during the 14 days preceding symptom onset or receipt of a positive test result.
- Among these cases of COVID-19 attributed to the Omicron variant, 34 (79%) occurred in persons who completed the primary series of an FDA-authorized or approved COVID-19 vaccine ≥14 days before symptom onset or receipt of a positive SARS-CoV-2 test result, including 14 who had received an additional or booster dose;
- Five of the 14 persons had received the additional dose <14 days before symptom onset.
- Six (14%) persons had a documented previous SARS-CoV-2 infection.
The most commonly reported symptoms were cough, fatigue, and congestion or runny nose.
One vaccinated patient was hospitalized for 2 days, and no deaths have been reported to date.
Case investigations have identified exposures associated with international and domestic travel, large public events, and household transmission.